vTv Therapeutics (VTVT) Depreciation & Amortization (CF) (2014 - 2026)

vTv Therapeutics has disclosed Depreciation & Amortization (CF) across 13 years of filings, most recently posting $1000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $1000.0, down 88.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $8000.0 (down 89.47% YoY), and the FY2025 annual result was $16000.0, down 82.02% from the prior year.
• Depreciation & Amortization (CF) came in at $1000.0 for Q1 2026 at vTv Therapeutics, down from $2000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $31000.0 in Q4 2022 to a low of $1000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $22000.0 (2022), against an average of $17411.8.
• Across the five-year window, Depreciation & Amortization (CF) surged 40.91% in 2022 and tumbled 90.91% in 2025, its largest moves.
• vTv Therapeutics' Depreciation & Amortization (CF) stood at $31000.0 in 2022, then declined by 25.81% to $23000.0 in 2023, then dropped by 4.35% to $22000.0 in 2024, then sank by 90.91% to $2000.0 in 2025, then slumped by 50.0% to $1000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1000.0 (Q1 2026), $2000.0 (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.